Business Context and Reporting Period
This Form 8-K filing by Acadia Healthcare Company, Inc. (ACHC) reports a significant corporate governance event dated March 31, 2022. The filing announces the appointment of Christopher H. Hunter as the new Chief Executive Officer and a member of the Board of Directors, effective April 11, 2022. The Board was expanded from nine to ten directors to accommodate this appointment.
Key Financial Metrics
The filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and governance changes.
Material Changes
The primary material change is the leadership transition at the CEO level. Christopher H. Hunter replaces the previous leadership structure, bringing experience from Humana, TriZetto, and BlueCross BlueShield of Tennessee. Additionally, the Board of Directors size increased to ten members.
Guidance, Outlook, and Management Commentary
While no financial guidance is provided, the filing details the new CEO's compensation package and performance targets:
- Base Salary: $1,000,000 annually.
- Target Bonus: 100% of base salary (up to 200% maximum).
- Equity Awards: Initial grant of $1 million in Restricted Stock Units (RSUs) and $3.5 million in Performance Stock Units (PSUs).
- Performance Targets: PSUs are tied to adjusted EBITDA and adjusted earnings per share targets for the period January 1, 2022, through December 31, 2024.
- Severance: Significant severance provisions exist for termination without cause or resignation for good reason, including 1.5x salary/bonus (18 months) outside a Change in Control, and 2.0x salary/bonus (lump sum) within a Change in Control period.
- Transition: Former leadership Debbie Osteen will provide advisory services for $20,000 per month.
Investor Verification Checklist
- Verify the exact start date of Christopher H. Hunter's tenure (April 11, 2022) and the effective date of the Board expansion.
- Review the specific adjusted EBITDA and EPS targets established for the 2022-2024 performance period to assess PSU vesting potential.
- Confirm the terms of the consulting agreement with Debbie Osteen and its duration.
- Monitor future filings for the formal adoption of the performance metrics referenced in the PSU grant.